secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2024-12-09T23:59:59+00:00
Accession:  0001104659-24-126761
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio appoints William Fricker as interim CFO effective December 4, 2024
------------------------------------------------------------------------------

- William Fricker, 61, appointed interim CFO; most recently CFO of NeuroTrauma Sciences (Dec 2023-Apr 2024).
- Previously CFO at NRX Pharmaceuticals (2020-2021), taking it public, and CAO at Immunomedics (2018-2020) until sale to Gilead.
- Fricker served as independent CFO contractor for biotech firms from 2021-2023; CPA (inactive), started career at PwC.
- No related-party transactions; Fricker serves on contract basis without employment agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924126761/0001104659-24-126761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924126761/tm2430528d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-126761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer